Kitov Pharma (PPBT): Price-to-Projected Revenue Ratio
Investments in targeted pancreatic cancer therapy rely on the NT219 license under FDA supervision. The expected price-to-sales ratio on the GURU.Markets chart demonstrates the dynamics of this program, where captures the magnitude of this parameter. An asset-light strategy utilizing outsourced testing scales patents, although regional conflicts create risks for offices and block the export of innovations for Purple Biotech (PPBT).
PPBT (Kitov Pharma): analytical breakdowns and indicator data
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Purple Biotech|PPBT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Purple Biotech|PPBT - Aggregate Debt Obligations|Debts to Book Capitalization Kitov Pharma|PPBT - Company Long-Term Debt|Company Short-Term Debts Purple Biotech|Quick Liquidity purple-biotech.com
- business earnings and investment ratios data:
PPBT - Company Net Income|Future Profit Purple Biotech|PPBT - Market Price to Net Income Ratio|Forward P/E Multiple Purple Biotech Corp|PPBT - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Kitov Pharma|PPBT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Purple Biotech|PPBT - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months purple-biotech.com|PPBT - Earnings per share trend in current year|Net earnings per share growth forecast for next year Purple Biotech
- sales volume and revenue information:
Summary company analysis:Purple Biotech Ltd. PPBT
The forward P/S ratio compares the market value of Purple Biotech (PPBT) with projected sales, allowing for an assessment of the premium paid for future cash flows. Since the company depends on the outcomes of oncology drug clinical trials without current revenue, the projected P/S trend serves as an indicator of speculative market expectations regarding therapy commercialization and the risk of capital impairment.
Who Purple Biotech competes with
BeiGene - Forward Price-to-Revenue Multiple|Forward P/S Multiple Halozyme Therapeutics, Inc. HALO|RVMD - Price-to-Projected Revenue Ratio|Forward Price to Sales AAPG (Ascentage Pharma Corp)|CG Oncology, Inc. (CGON) - Price-to-Projected Revenue Ratio|Future Price to Revenue URGN (urogen.com)|Price-to-Projected Revenue Ratio Bicara Therapeutics|Price-to-Projected Revenue Ratio PSNL|Forward P/S Multiple ERAS|DCTH - Market Cap to Future Revenue Ratio|Y-mAbs Therapeutics - Forward Price-to-Revenue Multiple|Forward Price to Sales AURA|Candel - Forward P/S Multiple|ARAY: Price-to-Projected Revenue Ratio|SLS: Forward P/S Multiple|ACTU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Citius Oncology, Inc.|Market Cap to Future Revenue Ratio TuHURA HURA|Forward Price-to-Revenue Multiple TARA (Protara Therapeutics, Inc.)|Price to Expected Revenue Ratio FATE|Forward P/S Multiple WHWK (Aadi Bioscience)|TScan Therapeutics Inc (TCRX) - Market Cap to Future Revenue Ratio|Champions Oncology Corp - Forward P/S Multiple|XBiotech Inc. (XBIT) - Forward Price-to-Revenue Multiple|CVM: Forward P/S Multiple|OS Therapies Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Artiva - Future Price to Revenue|Price-to-Projected Revenue Ratio Adlai Nortye Ltd. (ANL)|VERU: Future Price to Revenue|Forward P/S Multiple TPST (Tempest Therapeutics, Inc.)|Xilio Therapeutics Inc - Price-to-Projected Revenue Ratio|RENB: Forward Price-to-Revenue Multiple|Mural Oncology plc - Price to Expected Revenue Ratio|KAPA: Forward P/S Multiple|Forward Price-to-Revenue Multiple OnKure Therapeutics|GDTC (CytoMed Therapeutics Ltd) - Forward P/S Multiple|Forward P/S Multiple Curis Corp|Price-to-Projected Revenue Ratio Apollomics, Inc. (APLM)|Tharimmune Corporation - Market Cap to Projected Revenue|Forward P/S Multiple ADVB (Advanced Biomed)|GNPX - Forward Price-to-Revenue Multiple|Calidi Bio - Forward P/S Multiple|Market Cap to Future Revenue Ratio Sunshine Biopharma Inc.|xeneticbio.com (XBIO) - Price-to-Projected Revenue Ratio|Salarius Pharma - Forward Price to Sales|Forward Price-to-Revenue Multiple AONC|BGNE: Forward Price to Sales|Forward P/S Multiple CKPT|Forward Price-to-Revenue Multiple elevationoncology.com ELEV|iCAD - Forward Price-to-Revenue Multiple|Forward P/S Multiple Ikena Oncology Inc. IKNA|NTBL - Price-to-Projected Revenue Ratio|Forward Price to Sales VIRX (Viracta Therapeutics)|MOR: Forward P/S Multiple|Market Cap to Future Revenue Ratio NAYA Biosciences Inc (NAYA)|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd
